Peter Ulintz

University of Michigan–Ann Arbor — United States

Medicine · Health Sciences

19h-index1.4kcitations139works1.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Brain Metastases and Treatment(38), Computational Drug Discovery Methods(33), Radiopharmaceutical Chemistry and Applications(27), Cancer Genomics and Diagnostics(26), Click Chemistry and Applications(21)

Publications139 total

PT1.03.01 Precision Medicine Platform to Guide the Treatment of NSCLC
Journal of Thoracic Oncology·2025
TRLS-04 ENHANCING PRECISION MEDICINE THROUGH FUNCTIONAL DRUG TESTING FOR PATIENTS WITH BREAST CANCER BRAIN METASTASES.
Neuro-Oncology Advances·2025Open Access
Abstract 1148: Longitudinal monitoring of circulating tumor cell burden and single-cell RNA profiling in ALK-positive NSCLC patients
Cancer Research·2025
Abstract 491: Molecular correlates of drug response to identify novel therapeutic combinations in triple-negative breast cancer
Cancer Research·2025
Germline mutations in PPP2R1B in patients with a personal and family history of cancer
JCI Insight·2025· 3 citedOpen Access
PCO25-212: Examining Molecular Features of Rare Brain Metastases Patient-Derived Xenograft Models
Journal of the National Comprehensive Cancer Network·2025
Abstract B013: Precision medicine platform to guide the treatment of NSCLC
Cancer Research·2025· 1 cited
8P Precision medicine drug testing platform to guide the treatment of EML4-ALK fusion lung cancers
ESMO Open·2024Open Access
Integrative Drug Screening and Multiomic Characterization of Patient-derived Bladder Cancer Organoids Reveal Novel Molecular Correlates of Gemcitabine Response
European Urology·2024· 18 cited
Examining molecular landscape and drug sensitivity profiles of patient-derived xenografts from resected brain metastases.
Journal of Clinical Oncology·2024
Precision medicine-based platform to guide the treatment of EML4-ALK driven lung cancers and other NSCLC in real time.
Journal of Clinical Oncology·2024
Abstract A009: Integrative drug screening and multi-omic characterization of patient-derived bladder cancer organoids reveals novel molecular correlates of chemotherapy response
Clinical Cancer Research·2024
Abstract PO2-16-01: Molecular correlates of drug response to guide therapy in triple-negative breast cancer
Cancer Research·2024
Abstract 7504: Longitudinal multi-omics characterization of circulating tumor cells from ALK positive NSCLC patients
Cancer Research·2024
Abstract 223: Precision medicine-based platform to guide the treatment of EML4-ALK fusion lung cancers and other NSCLC
Cancer Research·2024
Selective and Potent PROTAC Degraders of c-Src Kinase
ACS Chemical Biology·2023· 12 citedOpen Access
Precision Medicine-Based Platform to Guide the Treatment of EML4-ALK Lung Cancers and Other Non-Small Cell Lung Cancers
EMJ Oncology·2023Open Access
EP12.02-03 Judith Tam ALK Lung Cancer Research Initiative
Journal of Thoracic Oncology·2023Open Access
159P Precision medicine-based platform to guide the treatment of EML4-ALK fusion lung cancers and other NSCLC
ESMO Open·2023Open Access
136P Molecular correlates of drug response to guide therapy in TNBC
ESMO Open·2023Open Access
page 1 of 7Next →

Frequent Co-authors

Sofía D. Merajver(19), Nathan Merrill(11), Matthew B. Soellner(11), Karin M. Hardiman(10), Xu Cheng(10), Aki Morikawa(10), Liwei Bao(9), Joel K. Greenson(8), Eric R. Fearon(8), Philip Andrews(7), Habib Serhan(7), Jason Heth(6), María G. Castro(6), Athena Apfel(6), Carlos A. Aguilar(5), Nathalie M. Vandecan(5), Joel A. Yates(5), Arul M. Chinnaiyan(5), Zhifen Wu(4), Jinju Li(4)